NCT01239043View on ClinicalTrials.gov

Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination

PHASE2CompletedINTERVENTIONAL
Enrollment

139

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

April 30, 2011

Study Completion Date

February 29, 2012

Conditions
MeningitisMeningococcal MeningitisMeningococcal Infections
Interventions
BIOLOGICAL

Menomune®: A, C, Y, W 135 Meningococcal Polysaccharide

0.5 mL, Subcutaneous

BIOLOGICAL

Menactra®: Meningococcal (A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate

0.5 mL, Intramuscular

Trial Locations (6)

40004

Bardstown

84088

West Jordan

85251

Scottsdale

87108

Albuquerque

98101

Seattle

99202

Spokane

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY